Clinical Asthma Phenotypes and Therapeutic Responses

Table 4

Effect of montelukast versus fluticasone on pulmonary function and airway inflammatory biomarkers in wheezy phenotype group (G3).

	G3A			G3B			𝑃
	Before treatment	After treatment	Percentage change	Before treatment	After treatment	Percentage change
FEV1% predicted	69.2±1.8	75.2±2.1 *	8.6%	70.2±1.1	80.1±0.9 *	14.1%	<0.001
Total sIgE (IU/mL)	182.2±13.2	175.1±11.2	3.89%	184.8±11.8	165.8±9.8	10.28%	0.9
Peripheral eosinophilic%	7.4±0.9	4.2±0.19 *	−43.24%	6.9±0.8	2.8±0.2 *	−59.42%	<0.001
sECP (𝜇g/L)	50.2±7.1	32.3±6.2 *	−35.65%	47.8±7.1	22.9±4.3 *	−52.09%	<0.001
sICAM-1 (ng/mL)	701.9±59.2	692±63.2	1.41%	708±60.1	680±50.2	3.95%	0.8
sVCAM-1 (ng/mL)	860.2±219.8	823±198.2	4.32%	866.9±230.9	811±180.9	6.44%	0.78
sIL-2R (pg/mL)	3428±329.2	3411±230.1	0.49%	3439±330.2	3400±310.1	1.13%	0.86

G3A: wheezy group treated with montelukast. G3B: wheezy group treated with fluticasone.
Data are expressed as mean (SD). *𝑃<0.05 is significant (for each group before and after treatment).
Mann-Whitney 𝑈-test was used to compare both groups.